Article
Debate weighs merits of both modalities; further research may elucidate preferences
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
PulseSight doses first patient in PST-611-CT1
3 Things You Should Know About Interventional Glaucoma Comanagement
Health Canada approves aflibercept biosimilar Aflivu
Patient-Centered Treatment Strategies in the Management of nAMD and DME
A look at the vorolanib intravitreal insert compared with aflibercept for DME
Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema